Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with PertuzumabOtto Metzger, Ian E. Krop, Denise A. Yardley et al.|Cancer Discovery|2021Cited by 241
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancerMichalina Janiszewska, Kornélia Polyák, Shayna Stein et al.|JCI Insight|2021Cited by 42